Vibegron for ENergy Thinking and Resilience in Aging

Starting soon · Phase 3 · Has a placebo group

Conditions studied: Obesity

In brief

This 12-week randomized, double-blind, placebo-controlled trial will test the hypothesis that Vibegron (brand name GEMTESA) can improve energy metabolism, cardiometabolic risk factors, and physical and cognitive function in middle-aged and older adults with obesity.

Key facts

Study ID
NCT06987383
Run by
Wake Forest University Health Sciences
People needed
40
Starts
2026-09-01
Expected to finish
2028-07-01
Last updated by the study team
2026-08-04

Who can join

Age: 45 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.